Kadcyla savings card: as little as $0 a treatment with commercial insurance

Kadcyla is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How to pay the least

Given by your care team

Billed by the clinic

Kadcyla is given by a doctor or nurse, not picked up at a pharmacy.

Ask your care team or your plan what you’d pay before your visit.

Compare every option

Brand nameKadcyla

Authorized genericado-trastuzumab emtansine

Regular genericado-trastuzumab emtansine

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldAsk the pharmacy

Same as Kadcyla?

The original

–

Brand nameThe maker’s card

Genentech Oncology Co-pay Assistance Program

Savings card from Genentech

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 a treatment

The card takes up to $25,000 a year off your co-pay.

Or call 1-888-249-4918.

In the maker’s words

“With the Genentech Oncology® Co-pay Assistance Program, eligible patients with commercial insurance could pay as little as $0 per treatment for KADCYLA.”

From the maker’s offer on kadcyla.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Kadcyla itself, from the same company, sold without the brand name, and usually for less. For now Kadcyla is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Kadcyla is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

HER2-positive breast cancer

What the FDA label says

KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for:

the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either:
- received prior therapy for metastatic disease, or
- developed disease recurrence during or within six months of completing adjuvant therapy.
the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.

Select patients for therapy based on an FDA-authorized test for KADCYLA

Source: the FDA label for Kadcyla (Genentech, Inc.), April 1, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to the clinic’s billing office.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/kadcyla/